Invention Application
- Patent Title: EFFECTS OF NF-kB SIGNALING INHIBITORS ON BED BUG RESISTANCE TO ORALLY PROVISIONED ENTOMOPATHOGENIC BACTERIA
-
Application No.: US17708829Application Date: 2022-03-30
-
Publication No.: US20220378046A1Publication Date: 2022-12-01
- Inventor: Jose Pietri
- Applicant: South Dakota Board of Regents
- Applicant Address: US SD Pierre
- Assignee: South Dakota Board of Regents
- Current Assignee: South Dakota Board of Regents
- Current Assignee Address: US SD Pierre
- Main IPC: A01N43/54
- IPC: A01N43/54 ; A01N63/27 ; A01N25/00 ; A01P19/00 ; A01P7/04

Abstract:
Treatment compositions for controlling bed bugs and methods of use, including reducing bed bug resistance to a biological control agent are disclosed. The treatment compositions can include both a NF-kB signaling inhibitor and biological control agent, such as, an entomopathogenic bacteria, to improve the treatment composition efficacy against bed bugs. Provisioning of a small molecule inhibitor of NF-kB signaling can increase the rate of bed bug mortality during infection with a bacterial entomopathogen. Increased mortality can be independent of direct effects of the inhibitor on bacterial growth and can be instead the result of a reduced ability of bed bugs to clear the infection when treated with the inhibitor.
Information query
IPC分类: